# MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes

> **NCT01273181** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 9 (actual)

## Conditions studied

- Metastatic Cancer
- Metastatic Renal Cancer
- Metastatic Melanoma

## Interventions

- **BIOLOGICAL:** PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes
- **DRUG:** Aldesleukin
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT01273181
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-12
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2015-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01273181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01273181, "MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01273181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*